companydata.dkEurofins BioPharma Product Testing Denmark Holding A/S: Financial statements 2024
CVR: 37064408
Eurofins BioPharma Product Testing Denmark Holding A/S (CVR 37064408) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -103,878 and a net result of DKK -1,877,244 compared with DKK 3,606,153 the year before. Equity amounted to DKK 16,430,649. The solvency ratio was 26.2%.
- Gross Profit
- -103,878 kr.
- Profit/Loss
- -1,877,244 kr.
- Equity
- 16,430,649 kr.
- Total Assets
- 62,761,321 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -104 t. | -1.9 mio. | 16.4 mio. | - |
| 2023 | - | -93 t. | 3.6 mio. | 20.1 mio. | - |
| 2022 | - | -88 t. | 7.9 mio. | 18.8 mio. | - |
| 2021 | - | -82 t. | 4.3 mio. | 15.2 mio. | - |
| 2020 | - | -80 t. | 5.3 mio. | 15.9 mio. | - |
How creditworthy is Eurofins BioPharma Product Testing Denmark Holding A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Eurofins BioPharma Product Testing Denmark Holding A/S has published its annual report for 2023. Gross profit came to DKK -92,640, and the net result was DKK 3,606,153.
About Eurofins BioPharma Product Testing Denmark Holding A/S
Eurofins BioPharma Product Testing Denmark Holding A/S is a Danish company of the type Aktieselskab based in Galten, founded in 2015. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Stefánia Pcolová. The company is owned by Eurofins Pharma Services LUX Holding SARL. In 2025, the company reported a gross profit of DKK -163,266 and a net result of DKK 8,356,614 compared with DKK -1,877,244 the year before. Equity amounted to DKK 24,787,263.